Evidence map›Paper›PMID 28511706›Full record

ArticleBMC pediatrics2017

Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity.

Markus Lundgren, Leigh Johnson Steed, Roy Tamura, Berglind Jonsdottir, Patricia Gesualdo, Claire Crouch, Maija Sjöberg, Gertie Hansson, William A Hagopian, Anette G Ziegler and 9 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 4 countries.

Markus LundgrenDepartment of Clinical Sciences, Diabetes and Celiac disease unit, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, 205 02, Malmö, Sweden. markus.lundgren@med.lu.se.ORCID 0000-0001-6394-7689
Leigh Johnson SteedCenter for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Roy TamuraHealth Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Berglind JonsdottirDepartment of Clinical Sciences, Diabetes and Celiac disease unit, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, 205 02, Malmö, Sweden.
Patricia GesualdoBarbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO, USA.
Claire CrouchPacific Northwest Diabetes Research Institute, Seattle, WA, USA.
Maija SjöbergDepartment of Physiology, Institute of Biomedicine, University of Turku, and Department of Pediatrics, Turku University Hospital, Turku, Finland.
Gertie HanssonDepartment of Clinical Sciences, Diabetes and Celiac disease unit, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, 205 02, Malmö, Sweden.
William A HagopianPacific Northwest Diabetes Research Institute, Seattle, WA, USA.
Anette G ZieglerInstitute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München, and Forschergruppe Diabetes e.V, Neuherberg, Germany.
Marian J RewersBarbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO, USA.
Åke LernmarkDepartment of Clinical Sciences, Diabetes and Celiac disease unit, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, 205 02, Malmö, Sweden.
Jorma ToppariDepartment of Physiology, Institute of Biomedicine, University of Turku, and Department of Pediatrics, Turku University Hospital, Turku, Finland.
Jin-Xiong SheCenter for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Beena AkolkarNational Institute of Diabetes & Digestive & Kidney Diseases, Bethesda, MD, USA.
Jeffrey P KrischerHealth Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Michael J HallerDepartment of Pediatrics, University of Florida, Gainesville, FL, USA.
Helena Elding LarssonDepartment of Clinical Sciences, Diabetes and Celiac disease unit, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, 205 02, Malmö, Sweden.
TEDDY Study Group
Lund University · SEPacific Northwest Diabetes Research Institute · USUniversity of Turku · FIAugusta University · USUniversity of South Florida · USTUM Klinikum · DE

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Edward L Melanson · 1995 to 2026
$32.6M
NIDDK Follow-up on Subjects and Immunological Assessments in The Environmental Determinants of Diabetes In The Young Study (TEDDY) (UC4)UC4DK117483 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2017 to 2020
$30.4M
Establish a Data Coordinating Center (DCC) for the Consortium for Identification UC4DK100238 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2014 to 2014
$28.9M
The Study of Epigenetics and Infections in The Environmental Determinants of Diabetes in the Young (TEDDY)UC4DK112243 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2016 to 2016
$27.0M
Data Coordinating Center (DCC) for the Consortium for Identification of Environmental Determinants of Diabetes in the Young (TEDDY) StudyUC4DK106955 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2015 to 2015
$20.0M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
The Environmental Determinants of Diabetes in Youth: Washington Clinical CenterU01DK063829 · NIDDK · PACIFIC NORTHWEST RESEARCH INSTITUTE · PI HAGOPIAN, WILLIAM A. · 2003 to 2022
$11.8M
The Environmental Determinants of Diabetes in the Young (TEDDY) StudyUC4DK063863 · NIDDK · HOSPITAL DISTRICT OF SOUTHWEST FINLAND · PI TOPPARI, JORMA · 2013 to 2013
$5.6M
The Environmental Determinants of Diabetes in Youth: Washington Clinical CenterUC4DK063829 · NIDDK · PACIFIC NORTHWEST RESEARCH INSTITUTE · PI HAGOPIAN, WILLIAM A. · 2013 to 2013
$4.6M
NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001427NIDDK NIH HHS U01 DK063829NIDDK NIH HHS UC4 DK063829NIDDK NIH HHS UC4 DK063863NIDDK NIH HHS UC4 DK100238NIDDK NIH HHS UC4 DK106955NIDDK NIH HHS UC4 DK112243NIDDK NIH HHS UC4 DK117483NLM NIH HHS HHSN267200700014C
6 · The paper itself

Abstract

backgroundThe use of analgesic antipyretics (ANAP) in children have long been a matter of controversy. Data on their practical use on an individual level has, however, been scarce. There are indications of possible effects on glucose homeostasis and immune function related to the use of ANAP. The aim of this study was to analyze patterns of analgesic antipyretic use across the clinical centers of The Environmental Determinants of Diabetes in the Young (TEDDY) prospective cohort study and test if ANAP use was a risk factor for islet autoimmunity.

methodsData were collected for 8542 children in the first 2.5 years of life. Incidence was analyzed using logistic regression with country and first child status as independent variables. Holm's procedure was used to adjust for multiplicity of intercountry comparisons. Time to autoantibody seroconversion was analyzed using a Cox proportional hazards model with cumulative analgesic use as primary time dependent covariate of interest. For each categorization, a generalized estimating equation (GEE) approach was used.

resultsHigher prevalence of ANAP use was found in the U.S. (95.7%) and Sweden (94.8%) compared to Finland (78.1%) and Germany (80.2%). First-born children were more commonly given acetaminophen (OR 1.26; 95% CI 1.07, 1.49; p = 0.007) but less commonly Non-Steroidal Anti-inflammatory Drugs (NSAID) (OR 0.86; 95% CI 0.78, 0.95; p = 0.002). Acetaminophen and NSAID use in the absence of fever and infection was more prevalent in the U.S. (40.4%; 26.3% of doses) compared to Sweden, Finland and Germany (p < 0.001). Acetaminophen or NSAID use before age 2.5 years did not predict development of islet autoimmunity by age 6 years (HR 1.02, 95% CI 0.99-1.09; p = 0.27). In a sub-analysis, acetaminophen use in children with fever weakly predicted development of islet autoimmunity by age 3 years (HR 1.05; 95% CI 1.01-1.09; p = 0.024).

conclusionsANAP use in young children is not a risk factor for seroconversion by age 6 years. Use of ANAP is widespread in young children, and significantly higher in the U.S. compared to other study sites, where use is common also in absence of fever and infection.

Indexed as

AcetaminophenAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalAntipyreticsAutoantibodiesAutoimmunityBiomarkersChild, PreschoolDiabetes Mellitus, Type 1Drug UtilizationEuropeFemaleFollow-Up StudiesHumansIncidenceInfantAcetaminophenAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalAntipyreticsAutoantibodiesBiomarkersAnalgesicsIslet autoimmunityProspective studiesType 1 diabetes

Identifiers

PMID28511706
PMCPMC5434629
OpenAlexW2615723295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.